CIK 0001677077
- Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811822909
- Phone
- +1 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- 4 Open-market sale Director sold 25,000 shares at $1.21 ($30,325)
- 4 Open-market sale Director sold 20,000 shares at $1.21 ($24,202)
- 4 Open-market buy 10% owner bought 100,000 shares at $1.10 ($110,450)
- 4 Exercise or conversion Director acquired 50,000 shares (option exercise)
- 4 Exercise or conversion Director acquired 50,000 shares (option exercise)
- 4 Exercise or conversion Director acquired 50,000 shares (option exercise)
- 4 Exercise or conversion Director acquired 50,000 shares (option exercise)
- 4 Other disposition 10% owner disposed of 57,016 shares (other)
- 4 Open-market buy 10% owner bought 22,500 shares at $1.15 ($25,961)
- 4 Exercise or conversion 10% owner acquired 2,250,000 shares (option exercise)
- 4 Open-market buy 10% owner bought 2,500 shares at $1.40 ($3,488)
- 4 Open-market buy 10% owner bought 5,000 shares at $1.29 ($6,450)
- 4 Exercise or conversion Director acquired 150,000 shares (option exercise)
- 4 Open-market buy 10% owner bought 7,000 shares at $1.66 ($11,619)
- 4 Open-market buy 10% owner bought 3,000 shares at $1.79 ($5,368)
- 4 Open-market buy 10% owner bought 3,000 shares at $1.93 ($5,775)
- 4 Open-market buy 10% owner bought 2,000 shares at $1.98 ($3,959)
- 4 Open-market buy 10% owner bought 8,000 shares at $1.91 ($15,290)
- 4 Open-market buy 10% owner bought 1,612 shares at $2.10 ($3,377)
- 4 Open-market buy 10% owner bought 38,000 shares at an average $2.24 ($84,969)
Page 6 of 9 · 170 filings